评估直接口服抗凝剂与华法林相比在极重度肥胖非瓣膜性心房颤动患者中的疗效和安全性：一项回顾性队列研究
"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".
作者信息
Ezaldin Shady, Abdelsalam Mahmoud, Annie Frank, Chumbe Julton Tomanguillo, Gharib Elie
机构信息
Cardiovascular Department, Charleston Area Medical Center, Charleston, WV, USA.
出版信息
Heliyon. 2025 Jan 3;11(1):e41596. doi: 10.1016/j.heliyon.2024.e41596. eCollection 2025 Jan 15.
Abstract
•DOACs are effective and safe in very morbidly obese AF patients (BMI ≥50 kg/m).•DOACs show similar stroke and bleeding risks as warfarin in this population.•Findings support DOACs in anticoagulation guidelines for very morbidly obese patients.
摘要
•直接口服抗凝剂（DOACs）在极度肥胖的房颤患者（体重指数≥50kg/m²）中有效且安全。
•在这一人群中，DOACs与华法林的中风和出血风险相似。
•研究结果支持在针对极度肥胖患者的抗凝指南中使用DOACs。
Zotero 插件